NEW YORK – Immunocore said last week that it has treated the first patient in a Phase I trial of its bispecific protein therapy IMC-P115C.
Through the trial, dubbed IMC-P115C-1005, Oxfordshire, UK-based Immunocore is evaluating the safety and preliminary efficacy of IMC-P115C in patients with advanced solid cancers who are HLA-A*02:01-positive and whose tumors express PRAME.
IMC-P115C is an immune mobilizing monoclonal T-cell receptor against cancer, or ImmTAC, designed to target PRAME with an extended half-life. The firm's ImmTAC therapies are meant to redirect patients' immune systems to kill their cancer cells by way of an anti-CD3 immune-activating effector function.
IMC-P115C targets the same PRAME peptide as another one of Immunocore's ImmTAC candidates, brenetafusp, but with a reduced half-life, which improves patient convenience by cutting back on the frequency of treatment administration.